Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers - Episode 7

Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

June 14, 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the benefits and challenges of DNA and RNA testing for NRG1 fusions in patients with pancreatic cancer.

EP. 1: Prevalence of NRG1 Fusions in Lung Cancer

EP. 2: Differences Between DNA and RNA Testing for NRG1

EP. 3: Standard Treatments for NRG1 Fusion+ NSCLC

EP. 4: Ongoing Research Efforts Targeting NRG1 in Lung Cancer

EP. 5: Efficacy With NRG1-Directed Agents in NSCLC

EP. 6: Prognosis, Rarity of NRG1+ Pancreatic Cancer

Now Viewing

EP. 7: Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

EP. 8: Standard Treatment Regimens for NRG1+ Pancreatic Cancer

EP. 9: Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

EP. 10: Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer

EP. 11: DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer

EP. 12: A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer

EP. 13: The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

EP. 14: Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

EP. 15: Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

EP. 16: The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

EP. 17: The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

EP. 18: Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

EP. 19: Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

EP. 20: NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers